和元生物出资335万元成立安星正合（长沙）生物技术有限公司，持股67%

Group 1 - The core point of the article is that Heyuan Biotechnology (Shanghai) Co., Ltd. has invested 3.35 million RMB to establish Anxing Zhenghe (Changsha) Biotechnology Co., Ltd., holding a 67% stake in the new company [1] - Anxing Zhenghe (Changsha) Biotechnology Co., Ltd. was established on January 5, 2026, with a registered capital of 5 million RMB and is located in Changsha City [1] - The company is involved in various sectors including the production and operation of medical devices, drug import and export, and research and development in cell technology and human stem cell technology [1] Group 2 - The company is authorized to engage in the production of second and third-class medical devices, as well as the rental and sale of medical equipment [1] - It also focuses on technology services, development, consultation, and the sale of hygiene products and disposable medical supplies [1] - The business activities are subject to approval by relevant authorities, and specific operations will commence only after obtaining the necessary permits [1]